pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
BioPharma Dive·7h ago·1 min read
save

Bausch + Lomb appoints board chair Thomas Appio as interim CEO after Brent Saunders departs

Oct 12, 2026·read at BioPharma Dive ↗Neutral

Bausch + Lomb announced that board chair Thomas Appio will serve as interim chief executive, taking over immediately from Brent Saunders, who is leaving the role.

Appio, who has held several leadership positions at the company since 2010 and became board chair in August, was praised for his deep knowledge of the business and global leadership experience. The company said his background positions him to build on momentum and guide the next phase of growth.

Analyst Daniel Clark of Leerink Partners noted that, despite the unexpected change, the firm remains confident in its fundamental trajectory and highlighted the recent raise in the 2026 earnings outlook as evidence of growing operating momentum.

source

This writeup was produced by pharmadog from original reporting by BioPharma Dive.

Original headline: “Bausch + Lomb swaps CEOs; Merck reveals anticipated eye drug data”

read at BioPharma Dive ↗
609 words · retrieved 1h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
BAUSCH9AMGEN2ASTRAZENECA2Merck & Co., Inc.Sanofi
drugs
TEZSPIRE4tezepelumab4DUPIXENT3dupilumab3ranibizumab2ranibizumab biosimilar2
topics
Ophthalmology4Immunology2Diabetic Macular EdemaType 2 Diabetes

related stories

  • Aug 28AstraZeneca, Amgen poised to challenge Dupixent’s reign with esophagitis winBioSpace
  • Aug 27New data could widen use of AstraZeneca, Amgen immune disease drugBioPharma Dive
  • Dec 22Fierce Biotech Fundraising Tracker '26: Matchpoint makes $150M; KymaThera corrals $80MFierce Biotech
  • Sep 8AZ's R&D chief Barr touts internal 'science success story' after IL-33 antibody's stellar showing in COPDFierce Biotech
  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive